The purpose is to find out if early treatment with rituximab can keep people in remission longer than regular monitoring. Participants will be followed for about two years, with clinic visits every few months to check symptoms, blood tests, and any side effects. When the early‑treatment plan is used, the medication is given through an IV (a drip into a vein), while all participants keep taking their standard medicines and report how they feel.

Success is measured by whether the disease stays inactive, meaning the Birmingham Vasculitis Activity Score stays at zero, and by recording any relapses, side effects, or changes in quality of life. A relapse means the disease becomes active again, shown by a higher score or new symptoms. The information gathered will help doctors decide the best way to prevent flare‑ups in these rare conditions.

The main aim of the trial is to find out whether either medication can lower the risk of developing new kidney stones and slow the progression of the disease. Participants will be followed for up to two years, with regular clinic visits where blood and urine samples are taken and simple imaging scans are performed to look for stones and assess kidney health. One of the key laboratory measures is the eGFR, which estimates how well the kidneys are filtering waste from the blood.

During the study, researchers will compare the occurrence of kidney stones, changes in kidney function, and overall physical and mental well‑being between the groups receiving the study medicines and those receiving a placebo. The information gathered will help determine if these treatments are useful for preventing stone formation and preserving kidney health in people with this condition.

The purpose of this research is to determine if Blinatumomab is safe and well-tolerated by patients with these conditions. The medication is given through an intravenous infusion, which means it is delivered directly into a vein. The treatment involves receiving the medicine over a period of 10 days, with a specific daily amount that has been carefully determined for safety.

During the study, patients will be monitored for 52 weeks (one year) to check how their body responds to the treatment. The research team will track any side effects that may occur and measure how well the treatment works by checking blood tests for specific antibodies and evaluating disease symptoms. This is an open-label study, which means all participants will receive the active medication.

The treatment being tested in this study is a medication called obinutuzumab, which is also known by its code name RO5072759. Obinutuzumab is given as an infusion, which means it is administered directly into the bloodstream through a vein. The purpose of the study is to see how effective obinutuzumab is in helping patients achieve remission, which means the disease becomes inactive or less severe. The study will also look at whether patients can stop taking steroids, a type of medication often used to reduce inflammation, after completing a gradual reduction in their dose.

Participants in the study will receive obinutuzumab infusions and will be monitored over a period of time to see how their condition responds. The study will last for about 12 months, with key assessments at 6 months and 12 months. Researchers will track the number of patients who achieve remission, any side effects experienced, and other health outcomes. The goal is to gather information on the safety and effectiveness of obinutuzumab for treating relapsing granulomatosis with polyangiitis.

The purpose of this research is to determine if iptacopan can help patients achieve and maintain a state where the disease is under control (remission). The medication comes in the form of hard gelatin capsules that are taken by mouth. Some participants will receive iptacopan, while others will receive a placebo along with standard care treatments. The study will last for 48 weeks, during which participants will have regular check-ups to monitor their health and how well the treatment is working.

Throughout the study, doctors will assess various aspects of the disease activity, including how well the kidneys are functioning and whether there are signs of blood in the urine. The medication being tested aims to work differently from existing treatments by targeting a specific part of the immune system that is involved in causing the blood vessel inflammation.

The trial will explore three different treatment approaches. The first approach involves using rituximab together with another type of medication known as a conventional disease-modifying antirheumatic drug (cDMARD), which could be methotrexate, azathioprine, or mycophenolate mofetil, with a preference for methotrexate. The second approach uses tocilizumab, and the third approach involves tofacitinib. These treatments will be compared to see which is most effective in helping patients achieve remission, which means the disease is no longer active.

Participants in the study will receive one of these treatments for up to 52 weeks. The study will monitor how well each treatment works in reducing disease activity and helping patients feel better. The trial will also look at how patients and doctors assess the disease’s activity and any side effects that may occur. The goal is to determine which treatment offers the best chance of remission for patients with GPA who have not responded to previous therapies.

The purpose of the study is to evaluate how effective Idefirix is when used alongside the standard care for patients with severe ANCA-associated vasculitis and lung bleeding. Participants in the study will receive either Idefirix or a placebo, in addition to the usual treatments for their condition. The study will monitor how quickly the levels of ANCA antibodies in the blood decrease after treatment, as well as other health outcomes such as lung and kidney function, and overall safety.

Throughout the study, researchers will observe participants for any changes in their condition, including improvements in lung function and any potential side effects. The study aims to provide valuable information on the potential benefits and safety of using Idefirix in treating this serious form of vasculitis. The trial is expected to continue until mid-2026, with recruitment of participants starting in 2024.